Home › Leucemia linfatica cronica › Illinois › Chicago
Studi clinici su Leucemia linfatica cronica a Chicago, IL
14 studi su Leucemia linfatica cronica cercano partecipanti presso sedi a Chicago e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
In reclutamentoFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- e altri 1
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
In reclutamentoFase 3
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
In reclutamentoFase 3
- Northwestern University, Chicago
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
In reclutamentoFase 3
- Northwestern University, Chicago
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In reclutamentoFase 3
- University of Chicago Medical Center, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
In reclutamentoFase 1
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- Northwestern University, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
In reclutamentoFase 1
- University of Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
In reclutamentoFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- The University of Chicago Medical Center, Chicago
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
In reclutamentoFase 4
- Northwestern University, Chicago
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
In reclutamentoFase 4
- Northwestern University, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Northwestern Memorial Hospital, Chicago
Studi su Leucemia linfatica cronica in altre città
- Boston, MA31 studi
- Columbus, OH28 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- Rochester, MN19 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Cincinnati, OH14 studi
- Nashville, TN13 studi
Altri studi a Chicago
- Cancro del polmone non a piccole cellule61 studi
- Cancro al seno58 studi
- Cancro (tutti i tipi)51 studi
- Cancro metastatico45 studi
- Cancro alla prostata45 studi
- Obesità41 studi
- Cancro ai polmoni41 studi
- Cancro ovarico36 studi
- Ictus34 studi
- Cancro colorettale33 studi
- Insufficienza cardiaca31 studi
- Sovrappeso28 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.